Abel Hall LLC Cuts Stake in GSK plc (NYSE:GSK)

Abel Hall LLC cut its holdings in shares of GSK plc (NYSE:GSK) by 5.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,773 shares of the pharmaceutical company’s stock after selling 672 shares during the quarter. Abel Hall LLC’s holdings in GSK were worth $432,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in GSK. Sunbelt Securities Inc. raised its holdings in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after acquiring an additional 302 shares in the last quarter. Mesirow Financial Investment Management Inc. increased its position in GSK by 2.0% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock valued at $682,000 after purchasing an additional 323 shares during the period. Rehmann Capital Advisory Group raised its holdings in GSK by 6.3% in the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after purchasing an additional 332 shares in the last quarter. Investment Partners Asset Management Inc. lifted its position in shares of GSK by 2.3% in the 3rd quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company’s stock worth $636,000 after purchasing an additional 344 shares during the period. Finally, Bond & Devick Financial Network Inc. boosted its stake in shares of GSK by 5.4% during the 3rd quarter. Bond & Devick Financial Network Inc. now owns 7,830 shares of the pharmaceutical company’s stock valued at $320,000 after purchasing an additional 400 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Stock Performance

Shares of GSK opened at $35.06 on Thursday. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The stock has a market cap of $72.67 billion, a P/E ratio of 22.77, a P/E/G ratio of 1.31 and a beta of 0.63. The business’s 50 day moving average price is $33.98 and its 200-day moving average price is $37.75. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on GSK shares. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Finally, Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Six analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.